Antimicrobial resistance (AMR) is a growing global health concern, with more than 2.8 million people sickened by drug-resistant infections annually in the United States. The Karius Test® is designed to support clinicians in combating AMR by quickly and accurately identifying bacterial species and associated AMR markers.
Traditional, culture-dependent diagnostics are limited in their ability to identify hard to culture or antimicrobial pre-treated organisms. The Karius Test's culture-independent approach using metagenomic next-generation sequencing provides results within one day from sample receipt for pathogen detection, and two days for bacterial AMR marker identification. With genotypic AMR marker detection across 18 bacterial pathogens and four classes of antimicrobials, the Karius Test empowers clinicians to tailor antimicrobial management for severe infections like endocarditis and pneumonia.
Since the launch of the Karius Test in 2016, Karius has continued to innovate and enhance its technology to help contribute to the battle against AMR.
Download this infographic to learn more about:
- The challenge of AMR
- Common limitations of traditional AMR detection
- Applications and benefits of the Karius Test
- The sample submission and results reporting timeline of the Karius Test
- The AMR markers for 4 classes of antimicrobials associated with 18 bacterial pathogens detectable with the Karius Test
